Health TrialsbyHealthPanel

Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma

ConditionNasopharyngeal Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorJiangsu Cancer Institute & Hospital

About this trial

This clinical research aims to explore potential biomarkers and validate molecular signatures' predictive and prognostic value in nasopharyngeal carcinoma.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with newly histologically confirmed nasopharyngeal carcinoma

No evidence of distant metastasis (M0)

Written informed consent

Disqualifiers

None

Trial population

Patients with newly histologically confirmed stage IVa nasopharyngeal carcinoma

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Intensity modulated radiation therapy (IMRT) combined with chemotherapy

    Radiation

    Intensity modulated radiation therapy (IMRT) combined with chemotherapy

Treatment groups

60 Participants
are divided into 1 treatment group
Group A: Observation Group1 intervention

Trial outcomes

Primary outcomes

1

major pathological response

Time frame
3 months after radiation therapy

Secondary outcomes

1

Progression-free Survival

Time frame
2 years after radiation therapy
2

Overall Survival

Time frame
2 years after radiation therapy

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jiangsu Cancer Institute & Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: